Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
BMS-986446 by Bristol-Myers Squibb for Alzheimer's Disease: Likelihood of Approval
BMS-986446 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Alzheimer's Disease. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's BMS-986446?
BMS-986446 is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Alzheimer's Disease. According to...